169 related articles for article (PubMed ID: 29954690)
21. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.
Moltzahn F; Karnes J; Gontero P; Kneitz B; Tombal B; Bader P; Briganti A; Montorsi F; Van Poppel H; Joniau S; Spahn M
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):31-7. PubMed ID: 25535100
[TBL] [Abstract][Full Text] [Related]
22. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.
Fossati N; Trinh QD; Sammon J; Sood A; Larcher A; Sun M; Karakiewicz P; Guazzoni G; Montorsi F; Briganti A; Menon M; Abdollah F
Eur Urol; 2015 Jan; 67(1):3-6. PubMed ID: 25217422
[TBL] [Abstract][Full Text] [Related]
23. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
[TBL] [Abstract][Full Text] [Related]
24. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.
Gandaglia G; Abdollah F; Schiffmann J; Trudeau V; Shariat SF; Kim SP; Perrotte P; Montorsi F; Briganti A; Trinh QD; Karakiewicz PI; Sun M
Prostate; 2014 Feb; 74(2):210-6. PubMed ID: 24132735
[TBL] [Abstract][Full Text] [Related]
25. Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-institutional database.
Schiavina R; Bianchi L; Borghesi M; Briganti A; Brunocilla E; Carini M; Terrone C; Mottrie A; Dente D; Gacci M; Gontero P; Gurioli A; Imbimbo C; La Manna G; Marchioro G; Milanese G; Mirone V; Montorsi F; Morgia G; Munegato S; Novara G; Panarello D; Porreca A; Russo GI; Serni S; Simonato A; Urzì D; Verze P; Volpe A; Martorana G
Int J Urol; 2016 Dec; 23(12):1000-1008. PubMed ID: 27620370
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of prognosis and gene expression in prostate cancer patients with site-specific visceral metastases.
Zhang P; Chen T; Yang M
Urol Oncol; 2024 May; 42(5):160.e1-160.e10. PubMed ID: 38433022
[TBL] [Abstract][Full Text] [Related]
27. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort.
Abdollah F; Sun M; Schmitges J; Tian Z; Jeldres C; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
Eur Urol; 2011 Nov; 60(5):920-30. PubMed ID: 21741762
[TBL] [Abstract][Full Text] [Related]
28. Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study.
Knipper S; Preisser F; Mazzone E; Mistretta FA; Palumbo C; Tian Z; Briganti A; Shariat SF; Saad F; Tilki D; Graefen M; Karakiewicz PI
Urol Oncol; 2019 Oct; 37(10):702-710. PubMed ID: 31103337
[TBL] [Abstract][Full Text] [Related]
29. The effect of age at diagnosis on prostate cancer mortality: a grade-for-grade and stage-for-stage analysis.
Gandaglia G; Karakiewicz PI; Abdollah F; Becker A; Roghmann F; Sammon JD; Kim SP; Perrotte P; Briganti A; Montorsi F; Trinh QD; Sun M
Eur J Surg Oncol; 2014 Dec; 40(12):1706-15. PubMed ID: 24915856
[TBL] [Abstract][Full Text] [Related]
30. Incidence trends and survival of metastatic prostate cancer with bone and visceral involvement: 2010-2019 surveillance, epidemiology, and end results.
Kadeerhan G; Xue B; Wu XL; Chen WN; Wang DW
Front Oncol; 2023; 13():1201753. PubMed ID: 37601697
[TBL] [Abstract][Full Text] [Related]
31. Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.
Larbi A; Dallaudière B; Pasoglou V; Padhani A; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
Prostate; 2016 Aug; 76(11):1024-33. PubMed ID: 27197649
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer characteristics and cancer-specific mortality of Native American patients.
Deuker M; Knipper S; Pecoraro A; Palumbo C; Rosiello G; Luzzago S; Tian Z; Saad F; Chun F; Karakiewicz PI
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):277-285. PubMed ID: 31695139
[TBL] [Abstract][Full Text] [Related]
33. Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases.
Bernstein AN; Shoag JE; Golan R; Halpern JA; Schaeffer EM; Hsu WC; Nguyen PL; Sedrakyan A; Chen RC; Eggener SE; Hu JC
J Urol; 2018 Jun; 199(6):1510-1517. PubMed ID: 29288121
[TBL] [Abstract][Full Text] [Related]
34. Differences between rural and urban prostate cancer patients.
Stolzenbach LF; Deuker M; Collà-Ruvolo C; Nocera L; Tian Z; Maurer T; Tilki D; Briganti A; Saad F; Mirone V; Chun FKH; Graefen M; Karakiewicz PI
World J Urol; 2021 Jul; 39(7):2507-2514. PubMed ID: 33155063
[TBL] [Abstract][Full Text] [Related]
35. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer.
Muralidhar V; Mahal BA; Nezolosky MD; Beard CJ; Feng FY; Martin NE; Efstathiou JA; Choueiri TK; Pomerantz MM; Sweeney CJ; Trinh QD; Vander Heiden MG; Nguyen PL
BJU Int; 2016 Aug; 118(2):279-85. PubMed ID: 26235660
[TBL] [Abstract][Full Text] [Related]
36. Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population.
Sheng W; Zhang H; Lu Y
Int Urol Nephrol; 2018 Aug; 50(8):1435-1444. PubMed ID: 29982959
[TBL] [Abstract][Full Text] [Related]
37. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.
Abdollah F; Sun M; Schmitges J; Thuret R; Tian Z; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):95-103. PubMed ID: 22330991
[TBL] [Abstract][Full Text] [Related]
38. Predicting survival of patients with node-positive prostate cancer following multimodal treatment.
Abdollah F; Karnes RJ; Suardi N; Cozzarini C; Gandaglia G; Fossati N; Bianchi M; Boorjian SA; Sun M; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol; 2014 Mar; 65(3):554-62. PubMed ID: 24094576
[TBL] [Abstract][Full Text] [Related]
39. Metastatic renal cell carcinoma: Patterns and predictors of metastases-A contemporary population-based series.
Chandrasekar T; Klaassen Z; Goldberg H; Kulkarni GS; Hamilton RJ; Fleshner NE
Urol Oncol; 2017 Nov; 35(11):661.e7-661.e14. PubMed ID: 28728748
[TBL] [Abstract][Full Text] [Related]
40. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
